JP6438396B2 - 不活化ワクチンを作製するための、ならびに組換えタンパク質をリフォールディング／可溶化させるための高圧デバイスおよび方法 - Google Patents

不活化ワクチンを作製するための、ならびに組換えタンパク質をリフォールディング／可溶化させるための高圧デバイスおよび方法 Download PDF

Info

Publication number
JP6438396B2
JP6438396B2 JP2015530066A JP2015530066A JP6438396B2 JP 6438396 B2 JP6438396 B2 JP 6438396B2 JP 2015530066 A JP2015530066 A JP 2015530066A JP 2015530066 A JP2015530066 A JP 2015530066A JP 6438396 B2 JP6438396 B2 JP 6438396B2
Authority
JP
Japan
Prior art keywords
pressure
high pressure
bar
inactivated
inactivation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015530066A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015529462A5 (OSRAM
JP2015529462A (ja
Inventor
ニコラ ピエール イヴ カルブレック
ニコラ ピエール イヴ カルブレック
ギルダス メリアン
ギルダス メリアン
ルネ ラバトゥ
ルネ ラバトゥ
リオネル ジェラント
リオネル ジェラント
Original Assignee
メリアル インコーポレイテッド
メリアル インコーポレイテッド
トップ アンデュストリー ソシエテ パール アクシオン サンプリフィエ
トップ アンデュストリー ソシエテ パール アクシオン サンプリフィエ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メリアル インコーポレイテッド, メリアル インコーポレイテッド, トップ アンデュストリー ソシエテ パール アクシオン サンプリフィエ, トップ アンデュストリー ソシエテ パール アクシオン サンプリフィエ filed Critical メリアル インコーポレイテッド
Publication of JP2015529462A publication Critical patent/JP2015529462A/ja
Publication of JP2015529462A5 publication Critical patent/JP2015529462A5/ja
Application granted granted Critical
Publication of JP6438396B2 publication Critical patent/JP6438396B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B2/00—Preservation of foods or foodstuffs, in general
    • A23B2/10—Preservation of foods or foodstuffs, in general by treatment with pressure variation, shock, acceleration or shear stress
    • A23B2/103—Preservation of foods or foodstuffs, in general by treatment with pressure variation, shock, acceleration or shear stress using sub- or super-atmospheric pressures, or pressure variations transmitted by a liquid or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01041—Sterol 24-C-methyltransferasee (2.1.1.41)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2103/05—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Sustainable Development (AREA)
JP2015530066A 2012-08-30 2013-08-30 不活化ワクチンを作製するための、ならびに組換えタンパク質をリフォールディング／可溶化させるための高圧デバイスおよび方法 Active JP6438396B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261694968P 2012-08-30 2012-08-30
US61/694,968 2012-08-30
US201361830425P 2013-06-03 2013-06-03
US61/830,425 2013-06-03
PCT/US2013/057426 WO2014036345A2 (en) 2012-08-30 2013-08-30 Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins

Publications (3)

Publication Number Publication Date
JP2015529462A JP2015529462A (ja) 2015-10-08
JP2015529462A5 JP2015529462A5 (OSRAM) 2016-09-15
JP6438396B2 true JP6438396B2 (ja) 2018-12-12

Family

ID=49162270

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015530066A Active JP6438396B2 (ja) 2012-08-30 2013-08-30 不活化ワクチンを作製するための、ならびに組換えタンパク質をリフォールディング／可溶化させるための高圧デバイスおよび方法
JP2015530070A Expired - Fee Related JP6405308B2 (ja) 2012-08-30 2013-08-30 キメラｋｓａｃタンパク質の発現及び高圧により可溶性タンパク質を製造する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015530070A Expired - Fee Related JP6405308B2 (ja) 2012-08-30 2013-08-30 キメラｋｓａｃタンパク質の発現及び高圧により可溶性タンパク質を製造する方法

Country Status (18)

Country Link
US (3) US9169302B2 (OSRAM)
EP (2) EP2890392B1 (OSRAM)
JP (2) JP6438396B2 (OSRAM)
KR (1) KR102208844B1 (OSRAM)
CN (3) CN104717976A (OSRAM)
AP (1) AP2015008331A0 (OSRAM)
AU (4) AU2013308627B2 (OSRAM)
BR (1) BR112015004463B8 (OSRAM)
CA (2) CA2883296A1 (OSRAM)
EA (1) EA031988B1 (OSRAM)
ES (1) ES2744709T3 (OSRAM)
HK (1) HK1211874A1 (OSRAM)
MD (1) MD4608C1 (OSRAM)
MX (3) MX381717B (OSRAM)
NZ (3) NZ705790A (OSRAM)
PH (1) PH12015500700B1 (OSRAM)
RU (1) RU2647568C2 (OSRAM)
WO (2) WO2014036345A2 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968749B2 (en) * 2006-07-21 2015-03-03 Universidade Federal De Minas Gerais—Ufmg Vaccine composition and immunization method
ZA201501696B (en) 2012-08-30 2016-01-27 Merial Ltd Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins
AU2013308627B2 (en) 2012-08-30 2016-10-27 Boehringer Ingelheim Animal Health USA Inc. Expression of chimeric KSAC protein and method of producing soluble proteins by high pressure
BR112015024860B1 (pt) 2013-03-28 2023-11-07 Access To Advanced Health Institute Polipeptídeo de fusão, polinucleotídeo isolado, composição compreendendo dito polipeptídeo, uso da dita composição para estimular uma resposta imune contra leishmania e método in vitro e kit de diagnóstico para detectar infecção por leishmania em uma amostra biológica
CN104758944B (zh) 2015-04-02 2017-11-28 中国科学院过程工程研究所 一种疫苗制剂及其制备方法和用途
JP2018082987A (ja) * 2016-11-25 2018-05-31 株式会社日立製作所 ウイルス不活化方法及びウイルス不活化装置
JP2020152644A (ja) * 2019-03-18 2020-09-24 国立大学法人愛媛大学 Ｖｎａｒのリフォールディング方法およびｖｎａｒの製造方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN112120012B (zh) * 2020-09-30 2022-03-22 广东康盾创新产业集团股份公司 一种car-t细胞冻存方法
BR102021000794A2 (pt) * 2021-01-15 2022-07-26 Fundação Oswaldo Cruz Proteína quimérica, kit, método para diagnóstico de leishmaniose, uso de uma proteína quimérica, composição vacinal contra leishmaniose visceral, e, uso de uma composição vacinal

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
JP2743177B2 (ja) * 1987-04-24 1998-04-22 財団法人阪大微生物病研究会 百日咳菌の培養方法、及び百日咳トキソイドとその混合ワクチン
JP4111403B2 (ja) 1996-10-11 2008-07-02 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫刺激ポリヌクレオチド／免疫調節分子複合体
US5980912A (en) 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
FR2771011B1 (fr) 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves
WO2000002901A1 (en) 1998-07-09 2000-01-20 University Technology Corporation High pressure refolding of protein aggregates and inclusion bodies
WO2000072703A1 (en) 1999-05-28 2000-12-07 UNIVERSITé LAVAL Inactivation of food spoilage and pathogenic microorganisms by dynamic high pressure
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
KR100863630B1 (ko) 1999-09-25 2008-10-15 유니버시티 오브 아이오와 리써치 파운데이션 면역자극성 핵산
US7615617B2 (en) 1999-10-25 2009-11-10 University Of Delaware Use of hydrostatic pressure to inhibit and reverse protein aggregation and facilitate protein refolding
WO2002056824A2 (en) 2000-08-10 2002-07-25 Boston Biomedica, Inc. Pressure cycling inactivation of pathogens in biological materials used for therapeutics or vaccines
US6635223B2 (en) * 2000-10-25 2003-10-21 Andreas Maerz Method for inactivating micro-organisms using high pressure processing
DK1434789T3 (da) * 2000-10-31 2008-07-07 Barofold Inc Forbedret proteindisaggregering og refoldning under tryk
WO2004024027A2 (en) 2002-06-07 2004-03-25 University Of Florida Endodontic files made using bulk metallic glasses
SE525457C2 (sv) 2002-06-24 2005-02-22 Flow Holdings Sagl Förfarande för åstadkommande av en tryckändring mellan två trycktillstånd, högtryckspressanordning samt användning av förfarande eller högtryckspressanordning
AU2004287284B2 (en) * 2003-11-05 2009-11-12 C.B.F. Leti, S.L. Unipersonal Use of specific histones for the treatment of parasitic diseases
US7993580B2 (en) 2004-08-24 2011-08-09 Baxter International Inc. Methods for the inactivation of microorganisms in biological fluids, flow through reactors and methods of controlling the light sum dose to effectively inactivate microorganisms in batch reactors
WO2007062174A2 (en) 2005-11-21 2007-05-31 Barofold, Inc. Devices and methods for high-pressure refolding of proteins
CN200945252Y (zh) * 2006-09-01 2007-09-12 天津市华泰森淼生物工程技术有限公司 手动开启式小型超高压生物处理设备
WO2008033556A2 (en) * 2006-09-15 2008-03-20 Barofold, Inc. High pressure treatment of proteins for reduced immunogenicity
WO2008124134A2 (en) 2007-04-05 2008-10-16 Barofold, Inc. High-pressure refolding of proteins in the presence of binding partners
US7829681B2 (en) * 2007-04-05 2010-11-09 Barofold Inc. High-pressure inclusion body solubilization and protease clipping of recombinant fusion proteins
EP2207890A4 (en) 2007-10-05 2010-12-15 Barofold Inc HIGH PRESSURE PROCESSING OF AGGREGATED INTERFERONS
RU2440137C1 (ru) * 2007-12-21 2012-01-20 Пфайзер Инк. Термообработанные бактерины и эмульсионные вакцины, полученные из таких термообработанных бактеринов
BRPI0800357A2 (pt) 2008-03-10 2009-10-27 Fundacao Oswaldo Cruz método para produção de uma vacina estabilizada
US8603808B2 (en) 2008-05-08 2013-12-10 Merial Limited Leishmania vaccine using sand fly salivary immunogen
US8410258B2 (en) * 2008-05-21 2013-04-02 Infections Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
AR073170A1 (es) 2008-05-21 2010-10-20 Infectious Disease Res Inst Vacunas de poliproteinas recombinantes para el tratamiento y diagnostico de leishmaniasis
US20100112660A1 (en) 2008-05-30 2010-05-06 Barofold, Inc. Method for Derivatization of Proteins Using Hydrostatic Pressure
US20110070219A1 (en) 2009-04-27 2011-03-24 Seefeldt Matthew B High pressure protein crystallization
US20120304872A1 (en) * 2010-02-01 2012-12-06 Avure Technologies Ab High-pressure arrangement with locking element preventing rotation of load basket
CN201781934U (zh) * 2010-04-14 2011-04-06 中国农业大学 一种小型框架自动式超高压设备
EP2600843B9 (en) 2010-07-19 2020-03-11 Pressure BioSciences, Inc. Therapeutic protein compositions having reduced immunogenicity and/or improved efficacy
AU2013308627B2 (en) * 2012-08-30 2016-10-27 Boehringer Ingelheim Animal Health USA Inc. Expression of chimeric KSAC protein and method of producing soluble proteins by high pressure
ZA201501696B (en) * 2012-08-30 2016-01-27 Merial Ltd Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins

Also Published As

Publication number Publication date
CN104717976A (zh) 2015-06-17
EA201500275A1 (ru) 2015-07-30
PH12015500700A1 (en) 2015-05-25
EP2890392B1 (en) 2019-04-17
JP2015528466A (ja) 2015-09-28
MX381717B (es) 2025-03-13
AU2017200301A1 (en) 2017-02-16
EA031988B1 (ru) 2019-03-29
KR102208844B1 (ko) 2021-01-27
CN104768577B (zh) 2020-06-09
US20170081372A1 (en) 2017-03-23
AU2013308623B2 (en) 2017-03-02
MX2015002699A (es) 2015-12-01
JP6405308B2 (ja) 2018-10-17
CN108578679A (zh) 2018-09-28
MX2021004478A (es) 2021-06-04
KR20150063403A (ko) 2015-06-09
US20140072594A1 (en) 2014-03-13
RU2647568C2 (ru) 2018-03-16
JP2015529462A (ja) 2015-10-08
BR112015004463A2 (pt) 2017-08-08
WO2014036345A3 (en) 2014-06-26
RU2015111255A (ru) 2016-10-20
BR112015004463B1 (pt) 2021-08-24
AU2017201724B2 (en) 2019-01-17
HK1211874A1 (zh) 2016-06-03
NZ705790A (en) 2016-06-24
US10364274B2 (en) 2019-07-30
US9169302B2 (en) 2015-10-27
AU2013308627A1 (en) 2015-04-09
WO2014036349A1 (en) 2014-03-06
PH12015500700B1 (en) 2018-11-28
CN104768577A (zh) 2015-07-08
MD4608B1 (ro) 2018-12-31
US20140065187A1 (en) 2014-03-06
NZ715459A (en) 2017-05-26
WO2014036345A2 (en) 2014-03-06
EP2890392A1 (en) 2015-07-08
AU2013308623A1 (en) 2015-04-02
NZ706288A (en) 2016-06-24
MD4608C1 (ro) 2019-07-31
AP2015008331A0 (en) 2015-03-31
AU2017201724A1 (en) 2017-03-30
ES2744709T3 (es) 2020-02-26
MX358782B (es) 2018-09-04
MD20150031A2 (ro) 2015-10-31
CA2883303A1 (en) 2014-03-06
AU2013308627B2 (en) 2016-10-27
CA2883296A1 (en) 2014-03-06
BR112015004463B8 (pt) 2022-06-28
US9315553B2 (en) 2016-04-19
EP2890393A2 (en) 2015-07-08
HK1211873A1 (en) 2016-06-03
MX2015002701A (es) 2015-12-01

Similar Documents

Publication Publication Date Title
JP6438396B2 (ja) 不活化ワクチンを作製するための、ならびに組換えタンパク質をリフォールディング／可溶化させるための高圧デバイスおよび方法
Hajam et al. Bacterial ghosts as adjuvants: mechanisms and potential
EP2114444B1 (en) Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
JP5226534B2 (ja) 熱可逆性水中油滴型エマルション
MX2013013277A (es) Composiciones inunogenicas de la glucoproteina g de los virus hendra y nipah.
TR201815419T4 (tr) Ospa'nin mutant fragmanlari ve bunlarla i̇lgi̇li̇ yöntemler ve kullanimlar
MX2010005622A (es) Vacuna del virus de la lengua azul y composiciones inmunogenicas, procedimientos de uso y procedimientos de producion de la misma.
US10080791B2 (en) Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins
WO2011153532A1 (en) Peptide particle formulation
EP2442825B1 (en) Method for the purification of protein complexes
CA2604488A1 (en) Formulations and process for production of bordetella bronchiseptica p68 antigen and vaccines
US20250099565A1 (en) Clostridium chauvoei vaccine and method of making
CN114573708B (zh) 副鸡禽杆菌ha融合蛋白及其三聚体、制备的疫苗组合物、制备方法和应用
ES2732301T3 (es) Procedimientos de preparación de rotavirus inactivado
EA008247B1 (ru) Конструкции нуклеиновых кислот для экспрессии генов
CN102481358A (zh) 对抗蓝舌病毒的异源性引发-加强免疫疗法
AU2018325528A1 (en) Streptococcus suis vaccines to protect against reproductive, nursery-age, and growing pig diseases and methods of making and use thereof
AU2014234982A1 (en) Cross-protection of bovines against B. trehalosi infection by a multi-valent vaccine
RU2643335C1 (ru) Инактивированная бивалентная гидроокись алюминиевая вакцина против кампилобактериоза собак
Iyer Gowrishankara Preformulation Development of a monovalent recombinant-based subunit vaccine, a multivalent recombinant-based subunit vaccine and a multivalent live attenuated viral vaccine.
TW201839130A (zh) 日本腦炎疫苗及其製備方法
HK1146238A (en) Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same
Simon et al. of adjuvants
HK1166950A (en) Heterlogous prime-boost immunization regimen against bluetongue virus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160729

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170529

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180622

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181017

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181116

R150 Certificate of patent or registration of utility model

Ref document number: 6438396

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250